Shennon Biotechnologies, a San Francisco, CA-based biotech company using a proprietary single cell platform to advance immunotherapies, raised $13M in Seed funding.
The round was led by DCVC, with participation from Foundation Capital, AV8 and angel investors.
The company intends to use the funds to further expand the capabilities of the platform and scale discovery efforts to build a pipeline of effective targets for solid tumors.
Founded in 2021 and led by Li Sun, Ph.D., CEO & Founder, Shennon Biotechnologies has developed a proprietary platform that can profile millions of immune cells functionally at the single cell level within a few hours, enabling the identification of TCR or antibody targets to develop more precise and effective immunotherapies. The company is developing a pipeline of effective cell therapy targets for the treatment of solid tumors and later autoimmune diseases.
In the last 1.5 years, ShennonBio has identified rare, functionally activated T cells and established collaborations with multiple clinical centers to study patient samples.